Related Experiment Videos
[The effect of pyrazidole on the middle molecule level during various modes of hypobaric hypoxia]
Abstract:
Content of middle mass molecules (MMM) was studied in blood plasma of rats treated with pyrazidol, the known inhibitor of monoamine oxidase of the A type. A distinct increase in the MMM nonpeptide component was detected both in intact animals and in the rats kept under hypoxic conditions (9,000 m, 3 hrs) after three administrations of pyrazidol. Under conditions of intermittent hypoxia higher increase of the nonpeptide component as well as an increase of the MMM peptide component were detected. The MMM blood fraction was also elevated in the animals adapted to hypoxia. A possible role of the MMM fraction in the pyrazidol-produced adaptation effect during hypoxia is discussed.
Insights
Pyrazidol, a monoamine oxidase A inhibitor, increased middle mass molecules (MMM) in rat blood plasma. This effect was pronounced under hypoxic conditions, suggesting MMM
Area of Science:
- Biochemistry
- Pharmacology
- Physiology
Background:
- Middle mass molecules (MMM) are implicated in various physiological processes.
- Pyrazidol is a known inhibitor of monoamine oxidase A (MAO-A).
- Hypoxia presents significant physiological challenges.
Purpose of the Study:
- To investigate the effect of pyrazidol on middle mass molecules (MMM) in rat blood plasma.
- To examine how pyrazidol influences MMM levels under both normal and hypoxic conditions.
- To explore the potential role of MMM in pyrazidol-induced adaptation to hypoxia.
Main Methods:
- Rats were treated with pyrazidol, a monoamine oxidase A inhibitor.
- Blood plasma was analyzed for middle mass molecules (MMM) content.
- Experiments were conducted under normoxic and hypoxic conditions (simulated high altitude).
- Intermittent hypoxia and hypoxia adaptation protocols were employed.
Main Results:
- Pyrazidol administration led to a significant increase in the nonpeptide component of MMM in intact rats.
- This increase in the nonpeptide MMM component was also observed in rats exposed to hypoxia after pyrazidol treatment.
- Intermittent hypoxia resulted in a greater increase in both nonpeptide and peptide MMM components.
- Animals adapted to hypoxia showed elevated levels of the MMM blood fraction.
Conclusions:
- Pyrazidol significantly alters middle mass molecule levels in rat blood plasma.
- The nonpeptide component of MMM is particularly responsive to pyrazidol, especially under hypoxic stress.
- Pyrazidol may influence adaptation to hypoxia through modulation of MMM.
- Further research is warranted to elucidate the precise role of MMM in pyrazidol's adaptive effects during hypoxia.